Dravet Syndrome: Next-Line Management After Topiramate or Dietary Therapy Has Not Controlled Seizures
In Dravet syndrome, when three or four antiseizure medications have already been tried and a further step — topiramate or an age-appropriate dietary therapy — has not achieved adequate seizure control, a defined next treatment line is indicated.
Previous line — failure condition
The prior treatment step involved topiramate, or dietary therapy
(classical ketogenic diet or modified Atkins diet, depending on the patient's age), deployed after
three or four earlier antiseizure medications had failed. The goal of that line was avoidance of
prolonged convulsive seizures and status epilepticus. Where that goal has not been met, escalation
to the next treatment line is appropriate.
Next-line approach (partial overview)
At this stage, the structured approach incorporates adjunctive options spanning neurostimulation
and a range of additional pharmacological agents. The primary clinical goal is reduction in seizure
frequency — with the expectation that outcomes are meaningful but partial: neurostimulation,
for example, typically yields a modest rather than complete reduction in seizure burden. Full
agent selection, sequencing, and clinical criteria are contained in the complete protocol.
References
DOI: 10.1111/epi.17274
- Phenytoin may be helpful for status epilepticus. "Other" includes vagal nerve stimulation, levetiracetam, zonisamide, bromides, clonazepam, and ethosuximide (for absences).
- Although vagus nerve stimulation was considered a therapeutic option, there was Strong consensus that valproic acid, clobazam, stiripentol, and ketogenic diet, and Moderate consensus that fenfluramine, cannabidiol, and topiramate should be trialed prior to such therapy.
- Vagus nerve stimulation in persons with DS usually leads to a <50% reduction in seizure frequency (PHYSICIANS: n = 12, 100%; CAREGIVERS: n = 5, 100%).
View source ↗